R Stock Recent News

Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced its new direct-to-consumer (DTC) "I Wish I Knew" campaign for Xifaxan® (rifaximin), the first and only medicine FDA approved for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Designed to raise awareness about OHE and the role of Xifaxan, "I Wish I Knew" seeks to educate and empower patients and caregivers to take proactive steps in managing their liver disease.

HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira's Multiplo® TP/HIV rapid test for use as a self-test in Canada. MedMira has been able to move forward with this label claim and avoid additional testing requirements (e.g.

WOBURN, MA / ACCESS Newswire / July 3, 2025 / Bridgeline Digital, Inc. (NASDAQ:BLIN), a leader in AI-driven marketing technology, announced today that HawkSearch has been ranked #1 in the 2025 Gartner® Critical Capabilities Report in the B2B Search Use Case. HawkSearch has been identified as #1 in the 2025 Gartner® Critical Capabilities Report in the B2B Search Use Case.

LONDON, July 02, 2025 (GLOBE NEWSWIRE) --  NE10 Vodka Limited, (“NE10”) and/or (the” Company”) a leading international drinks business with a strong emphasis on the production and distribution of premium flavored vodka and ready-to-drink cans, today announced the appointment of two seasoned Directors, further strengthening the Company's executive leadership team. With immediate effect, Scott Ryder and Simon Young will take their positions as National Sales and Commercial Directors respectively.

FORT LAUDERDALE, FL / ACCESS Newswire / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched NIOPEG®, the Company's first Biosimilar drug on the market. NIOPEG® is a Biosimilar comparable to the reference biologic drug NEULASTA® (Pegfilgrastim).

Austin, Texas--(Newsfile Corp. - June 30, 2025) - Citizens, Inc. (NYSE: CIA), a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today announced the Company was selected to rejoin the broad-market Russell 3000® index and the small-cap Russell 2000® index effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

HOUSTON, TX / ACCESS Newswire / June 30, 2025 / National Energy Services Reunited Corp. ("NESR" or the "Company") (NASDAQ:NESR)(NASDAQ:NESRW) an international, industry-leading provider of integrated energy services in the Middle East and North Africa ("MENA") region, today announced that the Company has joined the Russell 2000® Index and the Russell 3000® Index, effective as of the close of U.S. equity markets on June 27, 2025, as a result of the 2025 annual Russell Index reconstitution. The broad-market Russell 3000® Index includes the largest 3,000 U.S. public companies by market capitalization.

Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase ®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 4,800,000 share purchase warrants ("Warrants") expiring June 30th, 2025 to June 30th, 2028. The Warrants were issued on June 30th, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company.

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) expects to issue its second quarter 2025 results at approximately 7:00 a.m. Eastern Time on Thursday, July 24, 2025. The company will also host a conference call at 11 a.m. Eastern Time on the same day. The call will be webcast live and a replay will be available. Details for the call include: When: Thursday, July 24, 2025 from 11:00 a.m. to 12:00 p.m. Eastern Time   How: Live webcast: Ryder System Second Quarter 2025 Earnings Release Confere.

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC.